Although osimertinib has shown good efficacy in treating patients with NSCLC harboring the EGFR L858R mutation, its effectiveness is typically more pronounced in patients harboring the EGFR 19del mutation [6, 11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.